Role of vitamin D receptor activators on cardiovascular risk

Kidney International

Volumn 74, Issue SUPPL. 111, 2008, Pages

  Valdivielso, Jose M ^a   Ayus, Juan C ^b  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b Renal Consultants of Houston   (United States)

Author keywords

Cardiovascular disease; End stage renal disease; Left ventricular hypertrophy; Vascular calcification; Vitamin D; Vitamin D receptor activator

Indexed keywords

CALCITRIOL; PARICALCITOL; PHOSPHATE; PHOSPHORUS; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; DRUG DERIVATIVE; VITAMIN D;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MORTALITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; VASCULAR SMOOTH MUSCLE; ANIMAL; CALCINOSIS; CHRONIC DISEASE; DISEASE MODEL; KIDNEY DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REVIEW;

ANIMALS; CALCINOSIS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; RATS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 57049153962     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.545     Document Type: Conference Paper

References (87)

1. US Renal Data System. USRDS 2003 Annual Data Report: Atlas of End-Stage renal disease in the United States, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease, 2003.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119.
3. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.
4. Levin A. Prevalence of cardiovascular damage in early renal disease. Nephrol Dial Transplant 2001; 16(Suppl 2): 7-11.
5. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
6. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
7. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
8. Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17: 29-32.
9. Zimmermann J, Herrlinger S, Pruy A et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
10. Foley RN, Parfrey PS, Harnett JD et al. The prognostic importance of left-ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031.
11. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
12. Ayus JC, Frommer JP, Young JB. Cardiac and circulatory abnormalities in chronic-renal-failure. Semin Nephrol 1981; 1: 112-123.
13. Ayus JC, Mizani MR, Achinger SG et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16: 2778-2788.
14. Galetta F, Cupisti A, Franzoni F et al. Left ventricular function and calcium phosphate plasma levels in uraemic patients. J Intern Med 2005; 258: 378-384.
15. Strozecki P, Adamowicz A, Nartowicz E et al. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail 2001; 23: 115-126.
16. Marchais SJ, Metivier F, Guerin AP et al. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999; 14: 2178-2183.
17. Neves KR, Graciolli FG, dos Reis LM et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004; 66: 2237-2244.
18. Hayashi SY, Brodin LA, Alvestrand A et al. Improvement of cardiac function after haemodialysis. Quantitative evaluation by colour tissue velocity imaging. Nephrol Dial Transplant 2004; 19: 1497-1506.
19. Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1277-1285.
20. Harnett JD, Kent GM, Barre PE et al. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994; 4: 1486-1490.
21. Messerli FH, Schmieder R. Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension. Drugs 1986; 31(Suppl 4): 192-201.
22. Muiesan ML, Salvetti M, Rizzoni D et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091-1095.
23. Verdecchia P, Schillaci G, Borgioni C et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54.
24. Silberberg JS, Barre PE, Prichard SS et al. Impact of left-ventricular hypertrophy on survival in end-stage renal-disease. Kidney Int 1989; 36: 286-290.
25. Brown JH, Hunt LP, Vites NP et al. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994; 9: 1136-1142.
26. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
27. Nakamura S, Sasaki O, Nakahama H et al. Left ventricular hypertrophy is a risk factor independent of hypertension in survival of hemodialyzed patients. Ren Fail 2002; 24: 175-186.
28. Zoccali C, Benedetto FA, Mallamaci F et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-2774.
29. Wang AY, Wang M, Woo J et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15: 2186-2194.
30. London GM, Pannier B, Guerin AP et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767.
31. Zoccali C, Benedetto FA, Mallamaci F et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65: 1492-1498.
32. Paoletti E, Specchia C, Di Maio G et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004; 19: 1829-1834.
33. London GM. Left ventricular hypertrophy: why does it happen? Nephrol Dial Transplant 2003; 18: 2-6.
34. Ayus JC, Go AS, Valderrabano F et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dl. Kidney Int 2005; 68: 788-795.
35. Achinger SG, Ayus JC. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int Suppl 2005: 67(Suppl 95): S37-S42.
36. Walters MR, Wicker DC, Riggle PC. 1,25-Dihydroxyvitamin D3 receptors identified in the rat heart. J Mol Cell Cardiol 1986; 18: 67-72.
37. O'Connell TD, Simpson RU. Immunochemical identification of the 1,25-dihydroxyvitamin D3 receptor protein in human heart. Cell Biol Int 1996; 20: 621-624.
38. Merke J, Milde P, Lewicka S et al. Identification and regulation of 1,25-dihydroxyvitamin-D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin-D3 - studies in cultured bovine aortic endothelial-cells and human dermal capillaries. J Clin Invest 1989; 83: 1903-1915.
39. Kawashima H. Receptor for 1,25-Dihydroxyvitamin-D in a vascular smooth-muscle cell-line derived from rat aorta. Biochem Biophys Res Commun 1987; 146: 1-6.
40. McGonigle RJ, Fowler MB, Timmis AB et al. Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron 1984; 36: 94-100.
41. McGonigle RJ, Timmis AD, Keenan J et al. The influence of 1 alpha-hydroxycholecalciferol on left ventricular function in end-stage renal failure. Proc Eur Dial Transplant Assoc 1981; 18: 579-585.
42. Weishaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. II. direct and indirect effects. Am J Physiol 1987; 253: E675-E683.
43. Weishaar RE, Kim SN, Saunders DE et al. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol 1990; 258: E134-E142.
44. Wu JM, Garami M, Cheng T et al. 1,25 (OH)(2) vitamin D-3 and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577-1588.
45. O'Connell TD, Berry JE, Jarvis AK et al. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997; 272: H1751-H1758.
46. Lemmila S, Saha H, Virtanen V et al. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998; 18: 404-410.
47. Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
48. Kim HW, Park CW, Shin YS et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006; 102: c21-c29.
49. Xiang W, Kong J, Chen SC et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132.
50. Bodyak N, Ayus JC, Achinger S et al. Activated Vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810-16815.
51. Mancuso P, Rahman A, Hershey SD et al. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure- prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol 2008; 51: 559-564.
52. Baksi SN, Hughes MJ. Deficiency in dietary vitamin D, not calcium, alters noradrenergic responsiveness in rat atria in vitro. J Mol Cell Cardiol 1986; 18: 653-656.
53. Li YC, Kong J, Wei MJ et al. 1,25-Dihydroxyvitamin D-3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
54. Walters MR, Ilenchuk TT, Claycomb WC. 1,25-Dihydroxyvitamin D3 stimulates 45Ca2+ uptake by cultured adult rat ventricular cardiac muscle cells. J Biol Chem 1987; 262: 2536-2541.
55. O'Connell TD, Giacherio DA, Jarvis AK et al. Inhibition of cardiac myocyte maturation by 1,25-dihydroxyvitamin D3. Endocrinology 1995; 136: 482-488.
56. Li Q, Gardner DG. Negative regulation of the human atrial natriuretic peptide gene by 1,25-dihydroxyvitamin D3. J Biol Chem 1994; 269: 4934-4939.
57. Briese S, Wiesner S, Will JC et al. Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. Nephrol Dial Transplant 2006; 21: 1906-1914.
58. Finch JL, Brown AJ, Slatopolsey E. Differential effects of 1,25-dihydroxyvitamin D-3 and 19-nor-1,25-dihydroxy-vitamin D-2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999; 10: 980-985.
59. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38: S45-S50.
60. Martin KJ, Gonzalez EA, Gellens ME et al. Therapy of secondary hyperparathyroidism with 19-nor-1 alpha,25-dihydroxyvitamin D-2. Am J Kidney Dis 1998; 32: S61-S66.
61. Takahashi F, Finch JL, Denda M et al. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997; 30: 105-112.
62. Martin KJ, Gonzalez EA, Gellens M et al. 19-Nor-1-alpha-25- dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432.
63. Sprague SM, Lerma E, McCormmick D et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001; 38: S51-S56.
64. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
65. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
66. Cardus A, Gallego C, Muray S et al. [Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells]. Nefrologia 2003; 23(Suppl 2): 117-121.
67. Cardus A, Panizo S, Parisi E et al. Differential effects of vitamin D analogues on vascular calcification. J Bone Miner Res 2007; 22: 860-866.
68. Mazza A, Pessina AC, Gianluca P et al. Pulse pressure: an independent predictor of coronary and stroke mortality in elderly females from the general population. Blood Press 2001; 10: 205-211.
69. Fang J, Madhavan S, Alderman MH. Pulse pressure: a predictor of cardiovascular mortality among young normotensive subjects. Am J Hypertens 1999; 12: 12A.
70. Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
71. Wu-Wong JR, Noonan W, Ma JL et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 2006; 318: 90-98.
72. Slatopolsky E, Dusso A, Brown AJ. The role of phosphorus in the of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am J Med Sci 1999; 317: 370-376.
73. Jono S, Mckee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17.
74. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701.
75. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-1959.
76. Ohtake T, Kobayashi S, Moriya H et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005; 16: 1141-1148.
77. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867.
78. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
79. Chen NX, O'Neill KD, Duan D et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002; 62: 1724-1731.
80. Wada T, Mckee MD, Steitz S et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84: 166-178.
81. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: S34-S38.
82. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357.
83. Achinger SG, Ayus JC. Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? J Am Soc Nephrol 2006; 17: S255-S261.
84. Eknoyan G, Levin NW, Eschbach JW et al. Continuous quality improvement: DOQI becomes K/DOQI and is updated. National Kidney Foundation's Dialysis Outcomes Quality Initiative. Am J Kidney Dis 2001; 37: 179-194.
85. Weinreich T, De los RT, Gauly A et al. Effects of an increase in time vs frequency on cardiovascular parameters in chronic hemodialysis patients. Clin Nephrol 2006; 66: 433-439.
86. Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298: 1291-1299.
87. Ayus JC, Achinger SG, Mizani MR et al. Phosphorus balance and mineral metabolism with 3 h daily hemodialysis. Kidney Int 2007; 71: 336-342.